A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer

Not yet recruitingOBSERVATIONAL

Enrollment

1,030

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2026

Conditions

Esophageal Cancer

Interventions

DRUG

Camrelizumab

The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.

Trial Locations (1)

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Peking University

OTHER